A Phase 1 Study of MLN8237 in Japanese Patients with Relapsed and/or Refractory Non-Hodgkin's lymphoma
- Conditions
- on-Hodgkin's Lymphoma
- Registration Number
- JPRN-jRCT2080221799
- Lead Sponsor
- Takeda Pharmaceutical Company Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 24
1) Patients with relapsed and/or refractory Non-Hodgkin's Lymphoma that is diagnosed hisologically or cytologically
2) Patients with radiologically or clinically measurable diseases
3) Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 1
1) Prior treatment with Aurora kinase inhibitors
2) Prior treatment of allogeneic hematopoietic stem cells transplant, or organ transplant
3) Patients with brain or cerebrospinal invasion
4) Major surgery within 14 days prior to enrollment
5) Serious infection or infection that requires intravenous antibiotics within 14 days prior to enrollment.
6) Simultaneously diagnosed with or treated for another malignancy, or having a clinical history of primary malignancy in another organ(s)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method